Astex Pharmaceuticals provides positive update on SGI-110
In established ovarian cancer xenograft models, SGI-110 in combination with platinum significantly delayed tumor growth compared to platinum alone. The researchers also showed that SGI-110 induced demethylation and increased expression of several tumor suppressor and tumor differentiation genes. In addition, SGI-110 slowed the repair of platinum DNA damage. The company also announced that the ongoing clinical phase 2 expansion study in patients with myelodysplastic syndromes and acute myeloid leukemia has been expanded to approximately 200 patients by including an additional cohort of relapsed/refractory MDS patients to the ongoing three other cohorts.
